Form 6-K GENETIC TECHNOLOGIES For: Oct 07
FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
dated October 7, 2015
Commission File Number 0-51504
GENETIC TECHNOLOGIES LIMITED
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrants Name)
60-66 Hanover Street
Fitzroy
Victoria 3065 Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: October 7, 2015 |
| ||
|
| ||
|
GENETIC TECHNOLOGIES LIMITED | ||
|
| ||
|
| ||
|
By: |
/s/ Bronwyn Christie | |
|
|
Name: |
Bronwyn Christie |
|
|
Title: |
Company Secretary |
Exhibit 99.1
ASX ANNOUNCEMENT
6 October 2015
CFO transition
Melbourne, Australia, 6 October 2015: Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, Company) announces the following change in the role of Chief Financial Officer (CFO).
Mr. Kevin Fischer has been appointed CFO assuming his duties on Monday, 2 November 2015. Following a transition period, he will replace the current CFO Mr. Brian Manuel, who is leaving to pursue a personal business opportunity but will remain with the Company until the end of October 2015 to facilitate an effective handover.
With over ten years in senior finance roles with successful diagnostic companies, such as QIAGEN and Cellestis, Mr. Fischer is well qualified to take on the roles of CFO and joint Company Secretary. Mr. Fischer is a CPA and Chartered Secretary who has significant experience in the administration, financial management and reporting for international operations similar to those of Genetic Technologies.
Genetic Technologies thanks Mr. Manuel for his significant contribution to the Company.
FOR FURTHER INFORMATION PLEASE CONTACT
Mr. Eutillio Buccilli |
Candice Knoll (USA) |
Executive Director & Chief Executive Officer |
Blueprint Life Science Group |
Genetic Technologies Limited |
+ 1 (415) 375 3340, Ext. 105 |
+61 3 8412 7050 |
|
About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage womens health. The Companys lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus® improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGenplus® expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.
The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGenplus®, launched in October 2014, significantly expands the applicable market. The Company markets BREVAGenplus® to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons).
For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Safe Harbor Statement
Any statements in this press release that relate to the Companys expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and
are subject to change at any time, the Companys actual results may differ materially from expected results. Additional risks associated with Genetic Technologies business can be found in its periodic filings with the SEC.
Genetic Technologies Limited · Website: www.gtglabs.com · Email: [email protected] ABN 17 009 212 328
Registered Office · 60-66 Hanover Street Fitzroy Victoria 3065 Australia · Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia
Phone +61 3 8412 7000 Fax +61 3 8412 7040
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
- Travel + Leisure Co. and Allegiant Announce Multi-Year Marketing Agreement
- Trustmark Corporation Announces First Quarter 2024 Financial Results
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!